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Dear Editor, 
 
Neutropenia, defined as a sustained neutrophil count of less than 1.5 x 109/L, is a common 
hematological abnormality that can be either transient (causes include infection, drugs or im-
mune mediated) or chronic (causes include extrinsic factors such as nutritional and immune 
factors, or intrinsic defects such as bone marrow failure syndromes or specific neutropenic syn-
dromes) (Newburger and Dale, 2013). Identification of the JAK2 V617F mutation is a major 
diagnostic criterion for the classical myeloproliferative neoplasms (MPN) of polycythemia 
vera, essential thrombocythemia and primary myelofibrosis. However, this mutation is also ob-
served in other myeloid malignancies such as acute myeloid leukemia and myelodysplastic 
syndrome/MPN (MDS/MPN) with ring sideroblasts and thrombocytosis, albeit at a considera-
bly lower frequency than that of the classical MPN. Apart from MDS, in which diagnosis is 
based on number of cytopenias, morphologically dysplastic lineages, presence of ringed 
sideroblasts, peripheral blood and bone marrow blast counts, and cytogenetics (Arber et al., 
2016) neutropenia is not a diagnostic criterion for other myeloid malignancies. Despite this and 
the absence of a requirement for excluding JAK2 V617F in diagnostic algorithms for neutro-
penia (Gong et al., 2013; Palmblad et al., 2014) an isolated neutropenia anecdotally appears to 
be a continual, if infrequent trigger for requesting JAK2 V617F mutation analysis. 
A retrospective audit was therefore performed in order to address the value of screening for 
the JAK2 V617F mutation in patients presenting with neutropenia. In an eleven and a half year 
period from January 2006 to June 2017 inclusive, 15,627 diagnostic requests were received for 
JAK2 V617F identification at a molecular diagnostic centre for hematological malignancies. 
Clinical details of neutropenia were provided on 278 requests. Of these 278 requests, 45 
(16.2 %) had details of isolated neutropenia whereas the remaining 233 (83.8 %) had in addi-
tion, at least one further clinical feature noted including anemia, thrombocytopenia, bone mar-
row fibrosis, splenomegaly or hepatosplenomegaly, increased lactate dehydrogenase, or a leu-
coerythroblastic blood picture. The methodology for detection of the JAK2 V617F mutation 
was unchanged throughout the audit period. The JAK2 V617F was not detected in any of the 
patients with clinical details of isolated neutropenia but was detected in 14 of the 233 (6.0 %) 
patients with additional clinical details suggestive of a myeloid malignancy. 
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While the number of patients analysed with an isolated neutropenia remains modest, this 
audit suggests that testing for the JAK2 V617F mutation is not warranted in patients with neu-
tropenia unless accompanied by additional features suggestive of a myeloid malignancy. Ac-
knowledging evolution to MDS has been observed in a minority of patients with chronic neu-
tropenia (Fattizzo et al., 2015) prolonged follow up is required with targeted molecular analysis 
necessary when clinically indicated. 
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